CureVac’s Final Chapter: Nasdaq Exit Confirmed Following BioNTech Acquisition
Published on 12/26/2025 at 22:32 | Redaktion boerse-global.de
The independent journey of CureVac as a publicly traded company has reached its conclusion. The Tübingen-based vaccine developer is now on the verge of a Nasdaq delisting, a direct outcome of its successful acquisition by rival BioNTech. For remaining shareholders, a final countdown has begun, marking the end of the firm’s autonomy and paving the way for the compulsory buyout of minority interests.
BioNTech has cleared a critical milestone in the takeover process. Following the expiration of an additional acceptance period, the Mainz-based company now commands approximately 86.75 percent of CureVac’s outstanding shares. This figure comfortably surpasses the 80 percent minimum threshold required to proceed with the transaction.
Valued Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
